Talking Techniques | Rob Vries on organoids for drug discovery and the study of COVID-19

BioTechniques Digital Editor, Tristan Free, speaks to Rob Vries, CEO of Hubrecht Organoid Technology (Utrecht, Netherlands) otherwise known as the HUB. We explore the HUB’s use of organoids for drug development and to further study and improve the clinical treatments of diseases such as cystic fibrosis. After an analysis of the advantages of organoids over 2D cell cultures and animal models, we dive into how HUB’s organoids are being used to investigate COVID-19.